HSE has ‘almost exhausted’ its 2019 funding for new drugs
Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), was speaking after the HSE informed Biogen, manufacturer of Spinraza, it would not fund the drug
The HSE has “almost exhausted” the available funding it has for new drugs in 2019 just two months into the year, the state’s medicines watchdog has warned.
Professor Michael Barry, who heads up the National Centre for Pharmacoeconomics (NCPE), was speaking after the HSE informed Biogen, manufacturer of Spinraza, it would not fund the drug.
Barry’s comments will set off alarm bells amid the pharma sector, which has criticised the delays that it ...
